Original Article By David Lindfield
A Chinese biotech startup is making global headlines after claiming it has developed a pill capable of extending human life to 150 years, a bold assertion that arrives amid Beijing’s growing interest in state-backed longevity research.
Lonvi Biosciences, based in Shenzhen, says its capsule targets so-called “zombie cells,” damaged cells that accumulate with age and fuel inflammation and disease.
The company’s CEO, Ip Zhu, has framed the pill as more than another wellness fad.
“This is not just another pill,” Zhu said, describing the treatment as a breakthrough that could push human longevity into unprecedented territory.
“This is the Holy Grail.”
The pill’s core ingredient, procyanidin C1 (PCC1), is extracted from grape seeds.
In mouse trials, Lonvi claims the compound increased overall lifespan by 9.4 percent and extended life by 64 percent from the first day of treatment.
“Living to 150 is definitely realistic,” Chief Technology Officer Lyu Qinghua told The New York Times.
“In a few years, this will be the reality.”
China Moves Longevity Research Into the National Agenda
While the timeline is optimistic, the ambition fits China’s broader strategy.
Aging research has quietly become a state priority, grouped with artificial intelligence and advanced biotech in national development plans.
Chinese President Xi Jinping has reportedly discussed longevity initiatives with Russian leader Vladimir Putin, who speculated that organ transplants could bring “immortality.”
A decade ago, anti-aging science in China was dismissed as Western fringe research.
Today, it’s a booming sector backed by venture capital and government support.
“Nobody in China used to talk about longevity, only rich Americans,” said Gan Yu, co-founder of Shanghai’s Time Pie, a startup in the same field.
“Now, many Chinese are interested and have the money to extend their lives.”
A Pill for 150 Years?
Lonvi’s researchers say the real promise is not merely extending lifespan but delaying the onset of age-related illness.
They argue PCC1 strengthens cells, slows deterioration, and preserves energy production.
With a healthy lifestyle, they claim, individuals could potentially live well beyond 100, and perhaps even past 120.
But the claims remain firmly in the realm of laboratory speculation.
PCC1’s results exist only in mice.
No human trial has demonstrated anything close to the sweeping promises made in Lonvi’s marketing.
Despite this, the company continues presenting its pill as a technological certainty.
Whether it’s an early look at the future of modern medicine, or simply the latest repackaged version of the age-old promise that death can be negotiated, remains to be seen.
For now, the only guaranteed result is that the global longevity industry continues to grow, fueled by hype, billions in investment, and a public increasingly willing to buy whatever hope comes in a bottle.
Be the first to comment